Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the presence of residual disease after treatment remains associated with an increased risk of recurrence and death. This retrospective cohort study aims to evaluate the survival outcomes of patients with residual disease following neoadjuvant therapy for TNBC and to assess the association between clinicopathological characteristics and survival outcomes, including disease-free survival and overall survival

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Triple-Negative Breast Cancer (TNBC) Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases Triple Negative Breast Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag university

Sohag, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR).

Complete clinical, pathological, treatment, and follow-up data available in the medical records.

Exclusion criteria

Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery.

Patients with incomplete or missing essential clinical, pathological, or follow-up data.

Patients with a history of another primary malignancy that could affect survival analysis.

Treatment and study plan

Chemo-radiotherapy alone

Procedure

Chemo and radiotherapy before surgery

Not applicable- observational study

Other

Not applicable. This is a retrospective observational cohort study. No study intervention is administered. Data will be collected retrospectively from patients' medical records, and all treatments were provided as part of routine clinical care.

Primary outcomes

Disease free survival

Time frame: Up to 3 years

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Survival Outcomes of Residual Disease in Patients With Triple-Negative Breast Cancer Following Neoadjuvant Therapy: A Retrospective Cohort Study

Acronym: ReS-TNBC

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Jul 20, 2026
Registry last updated: Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting